Ernesto Zilberberg, MD
Psychiatry · North Andover, MANPI 1053346569
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,349 of the $141,172 with a category attached, or 73.2%. 20 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 44.3% of the total. 2025 is the largest year on record at $93,232, more than ten times the $158 reported in 2019. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 946 payments — averaging $149.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$63K
- Alkermes, Inc.$51K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16K
- AbbVie$3K
- Vanda Pharmaceuticals Inc.$1K
- Lundbeck LLC$1K
- plus $6K from 14 others
What the payments were for
- Consulting fees$11,1908%
- Speaking & faculty fees$103,34973%
- Travel & lodging$5,2444%
- Food & beverage$20,79915%
- Education$5910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 144 | $62,594 |
| Alkermes, Inc. | 136 | $50,687 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 113 | $16,321 |
| AbbVie(2 entities) | 117 | $2,513 |
| Vanda Pharmaceuticals Inc. | 85 | $1,402 |
| Lundbeck LLC | 66 | $1,239 |
| Johnson & Johnson | 41 | $1,237 |
| Otsuka America Pharmaceutical, Inc. | 51 | $1,104 |
| Neurocrine Biosciences, Inc. | 38 | $1,077 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $639 |
| Axsome Therapeutics, Inc. | 28 | $606 |
| Corium, LLC | 24 | $580 |
| E.r. Squibb & Sons, L.L.C. | 22 | $435 |
| Idorsia Pharmaceuticals US Inc | 8 | $190 |
| Collegium Pharmaceutical, Inc. | 8 | $164 |
| Eisai Inc. | 16 | $152 |
| Merck | 8 | $140 |
| Luye Pharma (USA) Ltd. | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$191,545
- UZEDY$49,708
- CAPLYTA$14,054
- Austedo XR$10,212
- REXULTI$319
- SPRAVATO$256
- ARISTADA$222
- Azstarys$128
- ARISTADA INITIO$111
- INGREZZA$111
How this compares
$141,172 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 31 | $229,460 |
| VraylarCariprazine Hcl | 126 | $196,307 |
| Invega SustennaPaliperidone Palmitate | 69 | $186,320 |
| BelsomraSuvorexant | 348 | $164,156 |
| UzedyRisperidone | 37 | $136,281 |
| SpravatoEsketamine Hcl | 67 | $129,572 |
| AuvelityDextromethorphan Hbr/Bupropion | 166 | $127,587 |
| IngrezzaValbenazine Tosylate | 15 | $123,895 |
| RexultiBrexpiprazole | 59 | $93,349 |
| LybalviOlanzapine/Samidorphan Malate | 50 | $79,728 |
| FanaptIloperidone | 33 | $73,078 |
| CaplytaLumateperone Tosylate | 41 | $69,217 |
| AristadaAripiprazole Lauroxil | 17 | $61,886 |
| TrintellixVortioxetine Hydrobromide | 62 | $38,605 |
| Quetiapine Fumarate | 1,964 | $35,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato | $1,237 | $545,353167 claims |
| AbbVieVraylar | $2,513 | $196,307126 claims |
| MerckBelsomra | $140 | $164,156348 claims |
| Alkermes, Inc.Lybalvi, Aristada | $50,687 | $141,61467 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $62,594 | $136,28137 claims |
| Axsome Therapeutics, Inc.Auvelity | $606 | $127,587166 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,077 | $123,89515 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,104 | $93,34959 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,402 | $73,07833 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $16,321 | $69,21741 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $639 | $47,69386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in North Andover
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Maurizio FavaBoston$120K
- Craig SurmanCambridge$111K
- Jessica IsomDorchester$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.